{"id":"deb-tace-plus-lenvatinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatic toxicity / elevated liver enzymes"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea / vomiting"},{"rate":null,"effect":"Hand-foot skin reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DEB-TACE (drug-eluting bead transarterial chemoembolization) is a locoregional therapy that uses microspheres loaded with doxorubicin to deliver high drug concentrations directly to liver tumors while occluding blood supply. Lenvatinib is a multi-kinase inhibitor targeting FGFR, VEGFR, RET, and other pathways to inhibit angiogenesis and tumor proliferation. The combination aims to enhance efficacy through local chemotherapy plus systemic anti-angiogenic activity.","oneSentence":"DEB-TACE delivers doxorubicin directly to hepatocellular carcinoma via drug-eluting beads, while lenvatinib inhibits multiple receptor tyrosine kinases to suppress tumor angiogenesis and growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:53.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), intermediate to advanced stage"}]},"trialDetails":[{"nctId":"NCT07157969","phase":"PHASE2","title":"ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-02-19","conditions":"HCC - Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT07156617","phase":"","title":"A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data","status":"NOT_YET_RECRUITING","sponsor":"Xuhua Duan","startDate":"2025-10-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":2000},{"nctId":"NCT06904183","phase":"PHASE2","title":"Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-04-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":320},{"nctId":"NCT06492395","phase":"PHASE3","title":"Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":178},{"nctId":"NCT05301842","phase":"PHASE3","title":"Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-03-28","conditions":"Hepatocellular Carcinoma","enrollment":760},{"nctId":"NCT06265883","phase":"","title":"Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2019-07-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":205},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT06194695","phase":"","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Ze-yang Ding, MD","startDate":"2022-02-01","conditions":"Cholangiocarcinoma Non-resectable","enrollment":100},{"nctId":"NCT06192784","phase":"PHASE2","title":"Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2023-12-09","conditions":"Cholangiocarcinoma Non-resectable","enrollment":36},{"nctId":"NCT05592197","phase":"NA","title":"Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2018-10-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT05718232","phase":"PHASE3","title":"SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03","conditions":"Advanced Hepatocellular Carcinoma","enrollment":136},{"nctId":"NCT04127396","phase":"PHASE4","title":"Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2019-09-01","conditions":"Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus","enrollment":72},{"nctId":"NCT04229355","phase":"PHASE3","title":"DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2021-02-02","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT03905967","phase":"PHASE3","title":"TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-06-16","conditions":"Advanced Hepatocellular Carcinoma","enrollment":336}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DEB-TACE plus Lenvatinib","genericName":"DEB-TACE plus Lenvatinib","companyName":"Guangxi Medical University","companyId":"guangxi-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DEB-TACE delivers doxorubicin directly to hepatocellular carcinoma via drug-eluting beads, while lenvatinib inhibits multiple receptor tyrosine kinases to suppress tumor angiogenesis and growth. Used for Hepatocellular carcinoma (HCC), intermediate to advanced stage.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}